Issue link: https://www.e-digitaleditions.com/i/1481142
News on R&D and progress in the treatment of respiratory diseases, such as asthma and COPD. Calendar: The industry organizations page of the Inhalation website provides descriptions and contact information for cross-industry organizations and groups that present educational conferences and workshops. Inhalation OctOber 2022 35 Tool diagnoses Parkinson's disease using breathing patterns CAMBRIDGE, MASSACHU- SETTS—PharmaTimes Online reported that a team of researchers from the Massachusetts Institute of Technology (MIT), in collaboration with the University of Rochester, the Mayo Clinic and Massachusetts General Hospital, have developed an artificial intelligence model that can detect Parkinson's disease (PD) only from reading a person's noctur- nal breathing patterns. e article noted that Parkinson's disease is the fastest growing neurological disease worldwide and is usually "notori- ously difficult" to detect because motor symptoms such as tremors, stiffness and slowness often do not appear until several years after dis- ease onset. e new tool is a neural network or series of connected algo- rithms that mimic the way a human brain works. In addition to deter- mining whether a patient has PD, the tool can assess the severity of an individual's PD and track their disease progression. "A relationship between Parkinson's and breath- ing was noted as early as 1817, in the work of Dr. James Parkinson," explained Dina Katabi, professor of electrical engineering and computer science at MIT and principal inves- tigator at the MIT Jameel Clinic. "Some medical studies have shown that respiratory symptoms mani- fest years before motor symptoms, meaning that breathing attributes could be promising for risk assess- ment prior to Parkinson's diagno- sis," she added. e assessment can be done every night, at home, while the person is asleep and without bodily contact. CALENDAR Please visit the industry organiza- tions page of the Inhalation web- site to find descriptions and contact information for cross- industry orga- nizations and groups that pres- ent educational conferences and workshops. https://www.inhalationmag.com/ industry-organizations to PharmaTimes Online. e tri- ple therapy inhaler is already reim- bursed in Scotland for maintenance treatment of asthma in adults not adequately controlled with a com- bination of a long-acting broncho- dilator inhalers and a high dose of inhaled corticosteroid and who experienced one or more asthma exacerbations in the previous year. RESPIRATORY MEDICINE NEWS Historic US bill welcomed by Asthma and Allergy Foundation of America WASHINGTON, DC—Accord- ing to Globe Newswire, passage by the United States Congress of the Inflation Reduction Act is being applauded by the Asthma and Allergy Foundation of America (AAFA). Recognizing the "direct link between climate change, aller- gies, asthma and health equity," AAFA has been advocating for many provisions in the legislation that will benefit people with asthma and allergies. e bill includes an historic $369 billion investment to combat climate change and aims by 2030, to reduce greenhouse gas emissions in the US by 40% from 2005 levels. Further, the US Environmental Protection Agency (EPA) will receive additional fund- ing to help address air pollution in and around schools. e bill also represents "a significant step to improve health care affordability for millions of Americans." Pro- visions include a $2,000 out-of- pocket cap for prescription drugs in Medicare Part D, which will help seniors and people with disabili- ties insured by Medicare to afford prescription medication. A 3-year extension of tax credits will ensure that millions who do not have employer- sponsored health insur- ance or do not qualify for Medicare or Medicaid will continue to ben- efit from subsidies that make mar- ketplace coverage more affordable. INDUSTRY NEWS continued from page 8 begins pharmacokinetic (PK) and pharmacodynamic (PD) stud- ies in humans. Fierce Pharma also commented that the news comes shortly after Recipharm expanded its pressurized metered dose inhaler (pMDI) capabilities. at expansion is intended to position the company to support pharmaceutical compa- nies as they transition to inhalers whose propellants have lower global warming potential (GWP). H&T Presspart to partner with OzUK Limited BLACKBURN, UNITED KING- DOM—H&T Presspar t has announced a partnership with OzUK Limited, a UK-based research laboratory, to provide H&T Presspart's customers with end-to-end support in bringing to market new chemical entities (NCEs) or generic metered dose inhalers (MDIs) for traditional asthma/COPD applications, as well as new systemic and CBD treat- ments. e company press release explained the collaboration will complement H&T Presspart's Inha- lation Product Technology Centre (IPTC), which offers and provides H&T Presspart's customers the full range of services to develop and market an MDI with conven- tional propellants, as well as new low GWP propellants, HFA 152a and HFO 1234ze. With GMP manufacturing accreditation at a partnering site, OzUK can also sup- port H&T Presspart customers in clinical trials. Chiesi's Trimbow inhaler recommended by NHS Scotland PARMA. ITALY—Chiesi has announced that the Scottish Med- icines Consortium (SMC) has recommended the company's tri- ple inhaler, Trimbow (beclometa- sone dipropionate/ formoterol/ glycopyrronium), as an option for use within National Health Ser- vice (NHS) Scotland, according